Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era.

about

Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era.

Item

http://www.wikidata.org/entity/Q47391106

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Relevance of prognostic index ...... lymphoma in the rituximab era.

@en

Relevance of prognostic index ...... lymphoma in the rituximab era.

@nl

type

Item

label

Relevance of prognostic index ...... lymphoma in the rituximab era.

@en

Relevance of prognostic index ...... lymphoma in the rituximab era.

@nl

prefLabel

Relevance of prognostic index ...... lymphoma in the rituximab era.

@en

Relevance of prognostic index ...... lymphoma in the rituximab era.

@nl

P1476

Relevance of prognostic index ...... lymphoma in the rituximab era.

@en

P2093

Cheolwon Suh

http://www.w3.org/2001/XMLSchema#string

Jihoon Kang

http://www.w3.org/2001/XMLSchema#string

Shinkyo Yoon

http://www.w3.org/2001/XMLSchema#string

P2860

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

Beta2-microglobulin: emerging as a promising cancer therapeutic target.

Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor.

P304

276-284

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5045/BR.2017.52.4.276

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29333404

http://www.w3.org/2001/XMLSchema#string

P932

5762738

http://www.w3.org/2001/XMLSchema#string